

# Comparison of Diagnostic Accuracy with Carbon Dioxide versus Iodinated Contrast Material in the Imaging of Hemodialysis Access Fistulas<sup>1</sup>

Karen O. Ehrman, MD  
Tim E. Taber MD  
Gregg M. Gaylord, MD  
Patricia B. Brown, RN  
James P. Hage, ME

Index terms: Carbon dioxide • Contrast agents, comparative studies • Dialysis, shunts, 91.494

JVIR 1994; 5:771-775

Abbreviations: AV = arteriovenous, PTFE = polytetrafluoroethylene

**PURPOSE:** Imaging of dialysis fistulas was performed with use of carbon dioxide and iodinated contrast material. Images were then compared to assess the quality and accuracy of CO<sub>2</sub> as a contrast agent.

**PATIENTS AND METHODS:** Thirty-two patients underwent digital subtraction imaging of the fistulas performed with both iodinated contrast material and CO<sub>2</sub> to evaluate the venous anastomosis. The images were blinded and the degree of stenosis was graded in 10% increments by two physicians. Statistical analysis including sensitivity, specificity, and accuracy of CO<sub>2</sub> images was performed.

**RESULTS:** There was no significant difference in physician ratings of the degree of venous stenosis ( $P > .30$ ). Estimation of the degree of stenosis was significantly higher with CO<sub>2</sub> than with ionic contrast material ( $P = .0001$ ). When iodinated contrast material is used as the gold standard, the sensitivity, specificity, and accuracy of CO<sub>2</sub> were 94%, 58%, and 75%, respectively.


**CONCLUSIONS:** CO<sub>2</sub> has a role as a contrast agent in the imaging of dialysis access grafts when the use of iodinated contrast material is of concern. CO<sub>2</sub> is safe for venous injections; however, it should not be used to evaluate the arterial anastomosis with the "reflux technique."

**C**URRENTLY, there are more than 450,000 patients receiving dialysis worldwide, with the vast majority of these patients requiring hemodialysis. This mode of renal replacement therapy, however, continues to be plagued by the lack of a trouble-free permanent venous access. The Scribner arteriovenous (AV) shunt, developed in 1960, provided the first reliable "permanent" hemodialysis venous access. This development was followed by the Cimino AV fistula and finally the prosthetic AV graft (1). The prosthetic graft, most commonly composed of polytetrafluoroethylene (PTFE), currently reigns as the most popular choice for a permanent hemodialysis access.

not without problems of its own. The most costly of these problems, both in terms of patient morbidity and healthcare dollars, is graft failure. Graft failures are most commonly due to venous anastomotic stenosis or intragraft stenoses (presumably due to neointimal hyperplasia secondary to recurrent needle cannulation) with resultant thrombosis, pseudoaneurysms, or infection (2).

Mechanisms for access salvage now involve both the surgical and radiologic fields. Procedures such as surgical thrombectomy and revision, pharmacologic thrombolysis, angioplasty, and atherectomy are increasingly common (3-7). The common denominator in all of these procedures is the use of a fistulo-

<sup>1</sup>From the Departments of Cardiovascular and Interventional Radiology (K.O.E., G.M.G.), Nephrology (T.E.T.), and Medical Research (P.B.B., J.P.H.), Methodist Hospital of Indiana, 1701 N Senate Blvd, Indianapolis, IN 46206. From the 1993 SCVIR annual meeting. Received June 4, 1993; revision requested July 31; revision received May 11, 1994; accepted May 17. Address reprint requests to K.O.E.



**Figure 1.** (a) Straight upper arm PTFE graft visualized with iodinated contrast material. Arrow denotes venous anastomotic stenosis. (b) Same graft seen with use of CO<sub>2</sub>. Arrow denotes venous anastomotic stenosis.

gram as a "roadmap" for any access revision.

In the past, images of the hemodialysis fistula were obtained with use of iodinated intravascular contrast agents. These agents, however, are associated with nephrotoxicity, further robbing the patient of residual renal function (8,9). The use of the newer nonionic contrast agents, while minimizing any allergic reactions, may not have any advantage over older ionic agents in terms of minimizing nephrotoxicity (10). The nonionic contrast agents are also significantly more expensive than ionic agents. A relatively inexpensive contrast agent that minimizes the risk for allergic reactions is needed.

In the past few years, in part through work by Hawkins et al (11), carbon dioxide has gained increasing acceptance as a contrast agent. This compound is exceedingly inexpensive. In addition, allergic or significant nephrotoxic reactions have not been documented in humans to our knowledge. For these reasons, we designed a study to evaluate the diagnostic accuracy of CO<sub>2</sub> versus iodinated contrast material in the diagnosis of PTFE graft stenoses in hemodialysis accesses.


#### PATIENTS AND METHODS

Thirty-two patients were selected for this study. Twenty-eight of these patients had been selected by virtue of their inclusion in another study. These 28 patients had been scheduled for routine imaging of the fistula 3 months following the placement of a PTFE graft. An additional four patients were selected as they were scheduled for imaging due to access malfunction (indications included increased recirculation time and previous thrombosis).


The patient population consisted of 16 women and 16 men. The mean age of the patients was 59.1 years and their mean time on dialysis was 9.2 months. Causes of renal failure included diabetes mellitus ( $n = 16$ ), hypertension ( $n = 10$ ), glomerulonephritis ( $n = 3$ ), systemic lupus erythematosus ( $n = 1$ ), familial nephritis ( $n = 1$ ), and autosomal dominant polycystic kidney disease ( $n = 1$ ). All accesses were upper arm PTFE grafts (Impra, Tempe, Arizona).

Diagnostic imaging of the fistulas was performed after percutaneous placement of a 4-F, 65-cm-long vertebral angle 1 (Mallinckrodt, St

Louis, Mo) catheter in the graft. The tip of the catheter was placed just proximal to the venous anastomosis. Ten milliliters of Iovue 300 (iopamidol; Squibb Diagnostic, Princeton, NJ) was injected manually for the iodinated studies and 40 mL of CO<sub>2</sub> was delivered manually for the CO<sub>2</sub> studies. All injections were boluses. The patients were in supine position with their arm at their side. All images were obtained with digital subtraction angiography. Acquisition rates of 2 frames per second for iodinated contrast studies and 6–15 frames per second for the CO<sub>2</sub> studies were used. The venous anastomosis was examined by using the identical projection for both contrast media (Fig 1). The venous anastomosis was chosen for specific evaluation due to its aforementioned association with graft thrombosis and the ability to compare independent evaluators' interpretations of degree of stenosis. The entire fistula (arterial anastomosis and central veins) was evaluated with iodinated contrast material to complete the examination. An independent person then blinded the pairings (CO<sub>2</sub> and iodinated contrast material) for each patient and two vascular radiologists (K.O.E. and G.M.G.) randomly



2.



4.


evaluated the films. The percentage stenosis at the venous anastomosis was estimated based on visual inspection and grouped by 10% increments (0–10%, 11%–20%, etc).

These were then defined as the physician ratings. The analysis of these data consisted of four parts. First, descriptive statistics were computed for the ratings given by the two radiologists. Second, a paired *t* test was performed to determine whether the observed difference in the ratings of CO<sub>2</sub> and iodinated contrast material for each patient was statistically significant. Third, an analysis of variance and Wilcoxon rank test were performed to determine whether the observed difference in the patient ratings were physician related. Fourth, the sensitivity, specificity,

and accuracy of CO<sub>2</sub> as a contrast agent were computed with use of iodinated contrast material ratings as the gold standard.

## RESULTS

Analysis of the data shows that little variability existed between the physicians' severity ratings (Figs 2, 3). The Wilcoxon rank test showed no significant difference in the physician ratings regardless of whether CO<sub>2</sub> or iodinated contrast material was used ( $P > .30$ ). When corresponding ratings of the venous anastomotic stenoses with the different contrast agents are compared, significant differences are seen, however. The paired *t* test indicated that



3.

Figures 2–4. Distribution of severity ratings by physician for (2) CO<sub>2</sub> and (3) nonionic contrast medium. In 2 and 3, light bars indicate rating by G.M.G.; dark bars indicate K.O.E. (4) Distribution of severity ratings by contrast medium. Light bars indicate nonionic media, and dark bars indicate CO<sub>2</sub>.

the degree of stenosis as determined with CO<sub>2</sub> fistulography is significantly higher on average than the ionic ratings ( $P = .0001$ ). The percentage stenosis seen on the CO<sub>2</sub> images, on average, was judged 16% higher than the stenosis on the corresponding iodinated images. The distribution of severity ratings by contrast medium indicated that there are almost twice as many severe stenoses diagnosed when CO<sub>2</sub> is used compared with iodinated contrast material (Fig 4). Thus, use of CO<sub>2</sub> results in an overestimation of the number of severe cases. It is this unequal distribution of cases that results in an overall significant difference in the correlation between the two agents. After combining the mild and mild-moderate categories as “no treatment” and the moderate-severe and severe categories as “treatment required,” the sensitivity, specificity, and accuracy ratings obtained with use of CO<sub>2</sub> as a contrast agent were 94%, 58%, and 75%, respectively. The positive predictive value was 69%, and the negative predictive value was 89%. The data also showed that there was no

significant improvement in the correlation of ratings if two views of the venous anastomosis were available for physician grading. Finally, all patients underwent physiologic monitoring, including pulse oximetry and electrocardiography, and no adverse events occurred due to CO<sub>2</sub> in this study.

## DISCUSSION

CO<sub>2</sub> is a nontoxic, nonallergenic gas that is rapidly absorbed and then excreted by the lungs. Its use as an angiographic contrast agent was first described by Dotter and Judkins in 1964 (12). Since that time, only a few reports have described the clinical utility of CO<sub>2</sub> for this purpose (11,13). Weaver et al in particular found CO<sub>2</sub> angiography provided diagnostic value in peripheral vascular disease (14). The advantages of using CO<sub>2</sub> as a contrast agent include its lack of nephrotoxicity or hyperosmolality. This combination of advantages is especially important in the population with end-stage renal disease in whom cardiovascular and renal impairment frequently coexist. In addition to these considerations, preservation of residual renal function is an advantage not to be ignored. The development of mechanisms for kinetic modeling have allowed physicians to objectively measure the adequacy of the dialysis prescription. These models have shown that residual renal function frequently contributes significantly to overall clearances (15,16). The use of potential nephrotoxins then becomes something to avoid. Finally, the minimal expense of CO<sub>2</sub> (\$20/tank) makes it even more attractive as an intravascular contrast agent.

Despite the advantages of CO<sub>2</sub>, the concern has been whether the image quality obtained with CO<sub>2</sub> was high enough to make diagnostic and therapeutic decisions. We chose to address this question by studying a specific population, the hemodialysis patient with end-stage renal dis-

ease. Specifically, we examined hemodialysis access (PTFE graft) fistulograms. Hemodialysis patients frequently require repeated radiologic examinations, as dictated by access failure. It was our hope that, by showing the reliability of CO<sub>2</sub> fistulograms, angiographers could feel confident about using the agent when avoidance of iodinated contrast material in high-risk patients is necessary. As outlined above, the degree of venous anastomotic stenosis—the most common site of intra-graft stenosis—was consistently overestimated slightly with CO<sub>2</sub>. This peculiarity of CO<sub>2</sub> makes this test highly sensitive but only moderately specific. This is important when a treatment decision is made based on the findings on a CO<sub>2</sub> fistulogram.

Several inherent properties of CO<sub>2</sub> may limit the accuracy of images obtained with this agent. The compressibility of the gas makes delivery in an even bolus difficult and results in an “explosive” injection. To lessen this effect, we cleared the catheter of blood by injecting 10 mL of CO<sub>2</sub> prior to the bolus. However, the use of a dedicated CO<sub>2</sub> injector would more reliably solve this problem. Unfortunately, we did not have access to this at our institution. The buoyancy of CO<sub>2</sub> has been an important consideration in acquiring consistent vascular images. With the patient supine, the gas layers anteriorly. To optimize filling of the arm fistula, it may be helpful in the future to elevate the arm or place the patient in the Trendelenburg position. Also advanced digital capabilities such as increased matrices, faster frame rates, and stacking of images may have improved our results with CO<sub>2</sub>.

After the study was terminated, we had the opportunity to use CO<sub>2</sub> to image entire grafts including the central veins and arterial anastomosis. Like the venous anastomosis, CO<sub>2</sub> could be used safely and adequately for evaluation of the central veins; however, problems arose when we attempted to evaluate the

arterial anastomosis with a “reflux” technique. In three of five patients in which this was attempted, there were significant, though transient, neurologic sequelae. After injection of CO<sub>2</sub> into the arterial anastomosis by compressing the venous limb of the graft just proximal to the catheter tip, two patients experienced seizures and a third patient experienced loss of consciousness with an associated 30-second respiratory arrest. We assume CO<sub>2</sub> refluxed retrograde into the brachial artery back to the subclavian and vertebral artery. Animal studies have supported the hazards of CO<sub>2</sub> in the cerebral circulation (17). Our current recommendation is to use CO<sub>2</sub> fistulography in patients with a known severe allergic reaction to nonionic contrast medium or in other high-risk patients such as those with congestive heart failure. If the arterial anastomosis needs to be evaluated, extreme caution should be used. Arm positioning and injection of small amounts of CO<sub>2</sub> may lessen the chance of reflux into the cerebral circulation.

## CONCLUSION

While iodinated contrast medium remains the standard in the evaluation of vascular structures, this study indicates the feasibility of CO<sub>2</sub> as a contrast agent for upper extremity fistulography. The image quality in the majority of cases was sufficient to make therapeutic decisions, however, the accuracy may be improved with better delivery, patient positioning, and refinements in digital capabilities. Limitations and dangers remain and should be considered when CO<sub>2</sub> is used.

## References

1. Fan PY, Schwab SJ. Vascular access: concepts for the 1990's. *J Am Soc Nephrol* 1992; 3:1-11.
2. Ney AL, Odland MD, Andersen RC. Causes and evaluation of incipient vascular access failure in chronic hemodialysis. *Semin Dialysis* 1991; 4:174-178.

3. Kumpe DA, Cohen MAH. Angioplasty/thrombolytic treatment of failing and failed hemodialysis access sites: comparison with surgical treatment. *Prog Cardiovasc Dis* 1992; 34:263-278.
4. Gordon DH, Glanz S, Butt KM, Adamsons RJ, Koenig MA. Treatment of stenotic lesions in dialysis access fistulas and shunts by transluminal angioplasty. *Radiology* 1982; 143:53-58.
5. Schilling JJ, Eiser AR, Slifkin RJ, Whitney JT, Neff MS. The role of thrombolysis in hemodialysis access occlusion. *Am J Kidney Dis* 1987; 10:92-97.
6. Ehrman KO, Gaylord GM. Thrombolytic therapy for occluded dialysis access grafts. *Semin Interv Radiol* 1992; 9:190-194.
7. Johnson DE, Hinochara T, Selmon MR, Braden LJ, Simpson JB. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study. *J Am Coll Cardiol* 1990; 15:419-425.
8. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. *Am J Med* 1990; 89:615-620.
9. Katzberg RW. Renal effects of contrast media. *Invest Radiol* 1988; 23:S157-S160.
10. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. *N Engl J Med* 1989; 320:149-153.
11. Hawkins IF. Carbon dioxide digital subtraction arteriography. *AJR* 1982; 139:19-24.
12. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technic and a preliminary report of its application. *Circulation* 1964; 30:654-670.
13. Takeda T, Ido K, Yuasa Y, et al. Intraarterial digital subtraction angiography with carbon dioxide: superior detectability of arteriovenous shunting. *Cardiovasc Intervent Radiol* 1988; 11:101-107.
14. Weaver FA, Pentecost MJ, Yellin AE, Davis S, Finck E, Teitelbaum G. Clinical applications of carbon dioxide/digital subtraction arteriography. *J Vasc Surg* 1991; 13:266-273.
15. Collins AJ, Keshaviah PR. Are there limitations to shortening dialysis treatment? *Trans Am Soc Artif Intern Organs* 1988; 34:1-5.
16. Lindsay RM, Henderson LW. Adequacy of dialysis. *Kidney Intl* 1988; 33:S92-99.
17. Coffey R, Quisling RG, Mickle JP, Hawkins IF, Ballinger WB. The cerebral effects of intraarterial CO<sub>2</sub> in quantities required for diagnostic imaging. *Radiology* 1984; 151:405-410.